Document:

EX-10.8

 Exhibit 10.8 

TECHNOLOGY SUBLICENSE AGREEMENT 

This Sublicense Agreement (“Agreement”) is made effective this 7th day of March, 2007, by and between Introgen Therapeutics, Inc., a
Delaware corporation (“Sublicensor”), and Introgen Research Institute, Inc., a Texas corporation (“Sublicensee”). 

RECITALS: 
 WHEREAS,
Sublicensor and Sublicensee are parties to agreements whereby Sublicensee has applied for National Institutes of Health (“NIH”) grant funding for research and commercial development of the Licensed Subject Matter (defined below) and
Sublicensor will provide services to Sublicensee in return for compensation; 
 WHEREAS, said NIH funding will fund research at the
University of Texas M.D. Anderson Cancer Center (“UTMDACC”), a component of the University of Texas System, which is the owner and licensor to Licensor of the Licensed Technology (defined below), and will provide funds to pay Sublicensor
for services it will provide to Sublicensee; 
 WHEREAS, Sublicensor is in the business of providing such services and desires to perform
the services and be paid for them; 
 WHEREAS, UTMDACC is an important collaboration partner and stockholder of Sublicensor and support of
UTMDACC is important to nurture and sustain a continued business relationship between Sublicensor and UTMDACC; 
 WHEREAS, Sublicensee
anticipates additional grant funding from NIH or other sources; 
 WHEREAS, such NIH funding will advance the development and
commercialization of the Licensed Technology; 
 WHEREAS, such NIH funding is, and in the future may be, in connection with Small Business
Administration (“SBA”) programs stipulating commercial development potential of funded research and development; and 
 WHEREAS,
Sublicensor owns forty-nine percent (49%) of the issued and outstanding stock of Sublicensee and will therefore benefit from such grant funding and research and development activities through its equity ownership of Sublicensee; 

NOW, THEREFORE, to assist Sublicensee in obtaining grant funding for research and development, which will benefit Sublicensor, and in
consideration of Sublicensee’s efforts to obtain grant funding, and in further consideration of the compensation to be paid Sublicensor for its services, and the expenditure of portions of such grant funding at UTMDACC which will also benefit
Sublicensor, and other good and valuable consideration, receipt and sufficiency of which is hereby acknowledged by Sublicensor, Sublicensor and Sublicensee agree as follows: 

 AGREEMENT 

1. Definitions. The capitalized terms set forth in this section have the following meanings for purposes of this agreement: 

 

	 	(a)	“Affiliate” means an entity in which Sublicensee owns at least fifty percent (50%) of the equity ownership. 

  

	 	(b)	“License Agreement” means the Patent and Technology License Agreement between Sublicensor and the Board of Regents of the University of Texas System (the “Board”) dated July 20, 1994, including
all amendments thereto. 

  

	 	(c)	“Sublicensed Patents” means those patents and patent applications described on Schedule A attached hereto. 

  

	 	(d)	“Patent Rights” has the same meaning in this Agreement as it has in Section 2.3 of the License Agreement, except that for purposes of this Agreement Schedule A attached to this Agreement shall be
substituted for the Schedule A which is attached to the License Agreement. From time to time during the term of this Agreement, upon request of either party, Sublicensor and Sublicensee shall promptly update Schedule A to this Agreement to include
all patents and patent applications that are then within the Patent Rights under this Agreement. 

  

	 	(e)	“Licensed Products”, “Licensed Technology” and “Licensed Subject Matter” shall have the same meanings herein as are attributed to them in the License Agreement, after giving effect to the
substitution of Schedule A to this Agreement for Schedule A of the License Agreement. 

  

	 	(f)	“Territory” means the Licensed Territory as such term is defined in the License Agreement. 

  

	 	(g)	“Field” means the Licensed Field as such term is defined in the License Agreement. 

  

	 	(h)	“Net Sales” means gross revenues received by Sublicensee, its Affiliates or sublicensees, from a Sale, less discounts actually granted, sales and use taxes actually paid, import and/or export duties actually
paid, outbound transportation costs actually paid or allowed, and amounts actually allowed or credited due to returns, not exceeding the original billing amount. 

  

	 	(i)	“Sale” or “Sold” means the transfer or disposition of a Licensed Product for value, or with respect to products which are services, the provision of such services on a
fee-for-service basis, to a party other than Sublicensee or an Affiliate. 

	 	(j)	“Sublicense Income” means all consideration received by Sublicensee from a sublicense in consideration of a sublicense of the Licensed Subject Matter, including, but not limited to, up-front payments, marketing, distribution, franchise, option, license, bonus and milestone payments and equity securities. However, Sublicense Income specifically excludes: payments received by Sublicensee from a
sublicense as a result of purchase or sale of debt or equity securities of Sublicensee by such sublicensee, and (ii) payments for research and development of Licensed Products; and (iii) any royalties that Sublicensee receives for the
sublicensee’s sale of Licensed Products. 

 2. Sublicense Grant. Sublicensor hereby grants to Sublicensee a non-exclusive, fully paid, royalty free, perpetual, non-cancellable sublicense to manufacture, have manufactured, use, and/or sell Licensed Products and to otherwise exploit
Licensed Technology for commercial or other purposes in the Field throughout the Territory, including the right to grant further sublicenses, it being intended that the sublicense herein granted covers all rights of Sublicensor in the Licensed
Subject Matter in the Field and in the Territory. For avoidance of doubt, it is intended hereby that this sublicense covers all rights of Sublicensor in the Sublicensed Patents and all of Sublicensor’s rights in any technical information, know
how, process, procedure, composition, biological materials, device, method, formula, protocol, technique, software, design, drawing, or data related to the subject matter of any Sublicensed Patent, whether or not covered by Patent Rights, which is
reasonably necessary for practicing an invention at any time covered by the Patent Rights. Sublicensee agrees to comply with the provisions of the License Agreement as they pertain to a sublicense, and to reasonably cooperate with Sublicensor in
performing its obligations under the Sublicense Agreement. 
 3. Patent Maintenance and Prosecution. Sublicensor agrees to maintain, prosecute and
continue in force all Sublicensed Patents, including preparing, filing, maintenance and prosecution of each Sublicensed Patent, as well as reissues, reexaminations and similar proceedings with respect to each Sublicensed Patent, and the conduct of
interferences, defense of oppositions, requests for term extensions, and similar proceedings with respect to each Sublicensed Patent; and including the payment of all license fees, royalties, annuities, government fees and other fees and costs for
the maintenance of such Sublicensed Patents. In the event that Sublicensor for any reason and at any time abandons or otherwise fails to maintain, prosecute, and enforce any Sublicensed Patent in any country in the Territory, Sublicensor shall give
Sublicensee reasonable advance written notice of such abandonment or other failure which notice shall in any event be given before Sublicensed Patent rights are lost in such country. In the event Sublicensor abandons or otherwise fails to maintain,
prosecute, or enforce any Sublicensed Patent in any country then Sublicensee shall have the right to assume the future maintenance, prosecution and enforcement, of such Sublicensed Patent; and upon such assumption by Sublicensee the license granted
herein shall automatically convert from non-exclusive to exclusive with respect to such Sublicensed Patent in each country in which Sublicensee assumes such obligations, without execution of any further
documents, and Licensee will become obligated to pay royalties as provided below. The above provisions notwithstanding, neither Sublicensor, nor Sublicensee after assumption of the obligation to maintain, enforce and prosecute any Sublicensed
Patent, shall be obligated to expend its funds for litigation in connection therewith. Subsequent to assuming the obligation to maintain, enforce, and prosecute any Sublicensed Patent, Sublicensee shall be free to abandon same on a country by
country basis. 

 4. Additional Consideration. In the event this license is converted from
non-exclusive to exclusive as provided above, Subicensee shall after the date of conversion pay additional consideration as follows: 
  

	 	(a)	All out of pocket expenses incurred by Sublicensor after the conversion date in filing, prosecuting, enforcing and maintaining Patent Rights in each country in which this license has become exclusive for so long as this
Agreement and such Patent Rights remain in effect in such country. 

  

	 	(b)	A running royalty equal to three percent (3%) of Net Sales attributed to Sales of Licensed Products by Sublicensee, its Affiliates, and its sublicensees, in each country in which this license has become exclusive,
subject to the following: 

 Royalties shall be due hereunder only on Sales of Licensed Products, the sale of which would
infringe a valid claim of a Licensed Patent in the country in which the Licensed Product is sold. To the extent that Sublicensee is required, by order of any court to obtain a license from a third party in order to practice the rights granted to
Sublicensee hereunder, or Sublicensee reasonably determines that such a license is necessary, then up to fifty percent (50%) of the royalties payable to such third party may be deducted from the royalties payable to Sublicensor hereunder for Sales
in that jurisdiction. Notwithstanding the foregoing, if Sales of a Licensed Product subject to royalty obligations hereunder are also subject to a royalty under one or more other agreements entered into by Sublicensor and Sublicensee, or between
Sublicensor or Sublicensee and the Board or any of its component institutions, Sublicensee may reduce the royalties payable hereunder by fifty percent (50%). To the extent such other agreements do not provide for a corresponding fifty percent (50%)
reduction in royalties payable thereunder to account for royalties payable under this Agreement, then royalties payable under this Agreement shall be reduced by the amount of royalties imposed on such Sales under said other Agreement, up to one
hundred percent (100%) of the royalties on such Sales which would otherwise be charged under this Agreement. For avoidance of doubt, royalties payable by Sublicensee hereunder are the only royalties attributable to Sublicensee’s Sales that will
be payable by Sublicensee. Sublicensor will be responsible for royalties payable to the Board under the License Agreement, or to other licensors, which are attributable to Sublicensee’s Sales. 

 

	 	(c)	All such payments are payable within thirty days after March 31, June 30, September 30, and December 31 of each year during the term of this Agreement, at which time Sublicensee shall also deliver to
Sublicensor a true and accurate report, giving such particulars of the business conducted by Sublicensee, its Affiliates and sublicensees during the preceeding three calendar months as necessary for Sublicensor to calculate Sublicensee’s
payments hereunder. At the time of delivery of each such report Sublicensee will pay the amount due for the period of the report. The reports are required even if no payment is due. 

	 	(d)	Fifteen percent (15%) of Sublicense Income received by Sublicensee, but only if and to the extent that such fee is owed by Sublicensor to its licensors. 

 

	 	(e)	During the term of this Agreement and for one year thereafter, Sublicensee will keep complete and accurate records of its, its Affiliates and its sublicensees Sales and Net Sales sufficient to enable the royalties and
other payments due hereunder to be determined. Sublicensee will permit Sublicensor or its representatives, at Sublicensor’s expense, to examine Sublicensee’s records during regular business hours in order to verify any report required
under this Agreement. If any amounts due Sublicensor hereunder are determined to have been underpaid in an amount equal to or greater than five percent (5%) of the amount due during the period so examined, then Sublicensee will pay the cost of the
examination plus accrued interest on the underpayment at the highest rate allowed by law. 

 5. Confidentiality. In connection with the
implementation of this Agreement, Sublicensee may receive confidential, scientific, financial, or product information from Sublicensor, and Sublicensor may receive the same from Sublicensee, including information relating to Licensed Products and
Licensed Technology. Such information, when given in writing, shall be marked or otherwise identified as confidential when disclosed or, in the case of information given verbally, shall be identified as confidential at the time of such verbal
disclosure. Both parties shall maintain the confidentiality of the Confidential Information received from the other party, not disclose it to others (except with the permission of the disclosing party), and use it only in connection with this
Agreement. Both parties will use reasonable efforts to assure that all of their employees, consultants, contractors and others who have access to Confidential Information through them comply with the confidentiality obligations of this section. The
parties’ obligation shall not apply to Confidential Information which: (i) was in the receiving party’s possession as evidenced by written records prior to disclosure for the other party; (ii) was at the time of disclosure or
becomes public through no fault of the receiving party; (iii) is disclosed to the receiving party by a third party who has no obligation of confidentiality to the disclosing party; (iv) is independently developed by the receiving party
without use of such Confidential Information of the other party. A party receiving Confidential Information may disclose such information as required by law, court order, or order of an administrative agency to be disclosed, provided, however, that
notice of such potential legally required disclosure shall be provided to the disclosing party so the disclosing party may seek a protective order, and the receiving party shall assist the disclosing party in the event the disclosing party seeks to
obtain such a protective order or use other legal means to protect the confidential nature of the information. This section shall survive termination of this Agreement. 

6. Additional Rights. To further assist Sublicensee in development of the Sublicensed Technology, and for the consideration stated above, Sublicensor
hereby assigns to Sublicensee all of Sublicensor’s rights in and to that certain “Patent License Agreement-Non-Exclusive” made by and between Sublicensor
and National Institutes for Health and Centers for Disease Control, agencies of the United States Public Health Service within the Department of Health and Human Services, dated August 17,1998, with
NIH-PHS Patent License number L-052-98/0, covering Patent Serial Number 60/024,386, with Smyth-Templeton, et al as the inventors.
Sublicensor acknowledges that this Sublicense Agreement constitutes a transfer of substantially the entire business of Sublicensor relating to operations which concern said Patent License Agreement. 

 7. Notices. Notices required or permitted hereunder shall be delivered by United States certified or
registered mail, return receipt requested, by email or other electronic transmission with confirmation of receipt, by hand delivery, or in any other manner in which delivery actually occurs, to the party at the address set forth below: 

Introgen Therapeutics, Inc. 
 301 Congress Avenue, Suite 1850

 Austin, Texas 78701 
 Attention David G. Nance, CEO 

Introgen Research Institute, Inc. 
 301 Congress Avenue, Suite
2025 
 Austin, Texas 78701 
 Attention Rodney Varner, President

 Notices deposited in the United States mail will be deemed received five days after deposit, postage paid, in an official United States mail receptacle.
Other notices will be deemed received only upon actual receipt. A party may change its address for notice by giving the other party notice of change in the manner provided herein. 

8. Term. This Agreement will continue from the date hereof until expiration of the License Agreement pursuant to section 14.1 thereof, unless sooner
terminated as provided below. This Agreement will survive earlier termination of the License Agreement pursuant to section 14.2 thereof or otherwise. 
 9.
Termination. This Agreement and the sublicense granted herein may be terminated by Sublicensor upon material default by Sublicensee, provided that no default will be deemed to have occurred until Sublicensor shall have given Sublicensee
written notice describing the default and the following period to cure: (a) thirty (30) days if the default is a failure to pay money when due, and (b) a reasonable period, in the case of any other default. Further sublicenses granted
hereunder shall survive termination of this Agreement. Sublicensee may terminate this Agreement as to any Sublicensed Patent, on a country-by-country basis, by giving
Sublicensor written notice of termination. All obligations of Sublicensee that accrue before termination shall survive termination by Sublicensee. 
 10.
Entire Agreement. This Agreement is the entire agreement of the parties with respect to the subject matter hereof, and supersedes all prior agreements between the parties with respect thereto. Without limiting the foregoing, this Agreement
and the rights granted herein supersede Sublicensee’s obligations contained in Section 9 of the Sublease Agreement between Sublicensee and Sublicensor’s wholly owned subsidiary, TMX Realty, Corporation and any other agreement between
the parties or their affiliates. TMX Realty Corportion will sign this Agreement solely to evidence its agreement to this section hereof. 

 11. Multiple Counterparts: Copies: Electronic Transmission. This Agreement may be executed in multiple
counterparts, each of which shall be binding on the parties who sign it. Photocopies of this Agreement, and copies transmitted by electronic means, shall be effective as originals. 

Signed effective as of the date first written above. 

LICENSOR: INTROGEN THERAPEUTICS, INC. 
  

			
	By:	 	 /s/ DAVID G. NANCE

		 	David G. Nance, CEO

 LICENSEE: INTROGEN RESEARCH INSTITUTE, INC. 

 

			
	By:	 	 /s/ RODNEY VARNER

		 	Rodney Varner, President

 Agreed as to the provisions of Section 10 only: 

TMX REALTY CORPORATION 
  

			
	By:	 	 /s/ DAVID G. NANCE

		 	David G. Nance, President

 SCHEDULE A 

LICENSED PATENTS 
 Item l: 

Patent Family Reference Number: 
 INGN:095 

Title: 
 Chromosome 3p21.3 genes are tumor suppressors 

Inventors: 
 L. Ji; J. Minna; J. Roth; M. Lerman 

Patent Application or Patent Numbers: 
 USA 20040016006 Serial
Number 101445,718 
 International: PCT/US2001/021781 
 Item
2: 
 Patent Family Reference Number: 
 INGN: 147 

Title: 
 Compositions and Methods Involving Gene Therapy and
Proteaseome Modulation 
 Inventors: 
 R. Ramesh; S. Chada

 Patent Application or Patent Numbers 
 USA: 111672,896 

International: PCT/US07/061883 
 Item 3: 

Patent Family Reference Number: 

 INGN:160 
 Title:

 Bioactive FUSl Peptides and Nanoparticle-Polypeptide Complexes 

Inventors: 
 L. Lin; R. Arlinghaus; T. Sun; L. Ji; B. Ozpolat;
G. Berestein-Lopez; J. Roth 
 Patent Application or Patent Number: 

USA: 20060251726, Serial Number 375544 
 International: PCT/US
2006/009044 
 Item 4: 
 Patent Family Reference Number:
INRP:083 
 Title: 
 Methods and Compositions of Non-Viral Gene Therapy for Treatment of Hyperproliferative Diseases 
 Inventors: 

R. Ramesh; J. Roth; T. Saeki; D. Wilson 
 Patent Application or
Patent Numbers: 
 USA: Serial No. 60/135,818 

International: PCT/US2000/014350 

 SCHEDULE A 

LICENSED PATENTS 
 (Updated) 

This is Schedule A to the Technology Sublicense Agreement between Introgen Therapeutics, Inc. and Introgen Research Institute, Inc., updated
in accordance with Section 1(d) thereof. 
 Item 1: 

Patent Family Reference Number: 
 INGN:095 

Title: 
 Chromosome 3p21.3 genes are tumor suppressors 

Inventors: 
 L. Ji; J. Minna; J, Roth; M. Lerman 

Patent Application or Patent Numbers: 
 USA 20040016006 Serial
Number 101445,718 
 International: PCT/US2001/021781 
 Item
2: 
 Patent Family Reference Number: 
 INGN: 147 

Title: 
 Compositions and Methods Involving Gene Therapy and
Proteaseome Modulation 
 Inventors: 
 R. Ramesh; S. Chada

 Patent Application or Patent Numbers 

 USA: 111672,896 

International: PCT/US07/061883 
 Item 3: 

Patent Family Reference Number: 
 INGN: 160 

Title: 
 Bioactive FUSl Peptides and Nanoparticle-Polypeptide
Complexes 
 Inventors: 
 L. Lin; R. Arlinghaus; T. Sun; L.
Ji; B. Ozpolat; G. Berestein-Lopez; J. Roth 
 Patent Application or Patent Number: 

USA: 20060251726, Serial Number 375544 
 International: PCT/US
2006/009044 
 Item 4: 
 Patent Family Reference Number:
INRP.083 
 Title: 
 Methods and Compositions of Non-Viral Gene Therapy for Treatment of Hyperproliferative Diseases 
 Inventors: 

R. Ramesh; J. Roth; T. Saeki; D. Wilson 
 Patent Application or
Patent Numbers: 
 USA: Serial No. 60/135,818 

International: PCT/US2000/014350 
 Item 5: 

Patent Family Reference Number: INGN 164 

 Title: 
 Methods
and Compositions Related to Novel hTMC Promoter and Vectors for Tumor-Selective and High-Efficient Expression of Therapeutic Genes 
 Inventors: 

L. Ji; B. Fang; J. Roth 
 Patent Application or Patent Numbers:

 11/372,246 
 Item 6: 

Patent family Reference Number: 
 INGN:162 

Patent Application or Patent Numbers: 
 60/845,934 

Updated effective the 5th day of May 2008. 

INTROGEN THERAPEUTICS, INC. 
  

			
	By:	 	 /s/ DAVID G. NANCE

		 	David G. Nance, CEO

 INTROGEN RESEARCH INSTITUTE, INC. 
  

			
	By:	 	 /s/ RODNEY VARNER

		 	Rodney Varner, PresidentEX-10.9

 Exhibit 10.9 

ASSIGNMENT AND COLLABORATION AGREEMENT 

This Assignment and Collaboration Agreement (“Agreement”) is made effective on the
13th day of April 2009, by and between Assignor and Assignee. For purposes hereof, capitalized terms herein have the meanings set forth on Annex A hereto. 

In consideration of the royalties to be paid by Assignee under the Sublicense, the obligations assumed by Assignee, the covenants of each
party to the other made herein, and other good and valuable consideration, receipt and sufficiency of which is hereby acknowledged by Assignor. Assignor and Assignee agree as follows: 

1. Assignment. Assignor hereby assigns the Sublicense, and all rights and privileges appurtenant thereto, to Assignee, its successors and assigns;
provided, however, that Assignor reserves unto itself, and Assignee grants back to Assignor, its successors and assigns, a perpetual, fully paid up, worldwide, non-exclusive, royalty free license to use and
practice the Licensed Technology, far non-commercial research purposes only. If and to the extent that the Sublicense or any Licensed Technology is not assignable, Assignor agrees to grant, and does hereby
grant, to Assignee, to and under the Sublicense and such Licensed Technology, a royalty-free. fully-paid, world-wide, perpetual, irrevocable, non-terminable, transferable, exclusive right and license, with the
right to grant and authorize sublicenses, to manufacture, have manufactured, use and/or sell Licensed Products, to practice any method, process or procedure and to otherwise exploit the Licensed Subject Matter, within the Territory for use within
the Field. If Assignor does not have the right to grant a license under the Sublicense or any such Licensed Technology of the full scope set forth above, then the license granted under such Sublicense and Licensed Technology shalt be of the broadest
scope that Assignor has the right to grant; subject to the aforesaid license back to Assignor for research purposes only. 
 The Sublicense
contains an assignment to Assignor from Introgen Therapeutics, Inc. of that certain Patent License Agreement made by and between Introgen Therapeutics, Inc. and National Institutes of Health and Centers for Disease Control, agencies of the United
States Public Health Service within the Department of Health and Human Services, dated August 17, 1998, with NIH-PHS Patent License Number
L-052-98/0 covering Patent Serial Number 60/024,386, with Smyth-Templeton, et al as the inventors (the “Smyth-Templeton License”). Assignor hereby assigns to
Assignee all of Assignors right, title and interest in and to the Smyth-Templeton license. Assignor acknowledges that this assignment constitutes a transfer of substantially all of Assignor’s business relating to the Smyth-Templeton License.

 2. Assumption. Assignee hereby assumes all obligations and liabilities of Assignor under the Sublicense, to the extent same accrue or arise after
the date hereof; including, without limitation, the obligation to pay royalties and license fees as provided therein. 
 3. Commercialization Efforts.
Assignee agrees to use reasonable commercial efforts to commercialize the Licensed Technology. 
 4. Collaboration. Assignor and Assignee agree to
collaborate with one another for the development of the Licensed Technology. 

 5. Collaborative Grant Funding. It is contemplated that Assignee and / or Assignor will apply for an NIH
SBIR Phase II grant and that Assignee may apply for other grant funds, with the primary purpose of each such grant being to advance the Licensed Technology toward commercialization. Each party agrees to use reasonable commercial efforts to apply for
and obtain contemplated grants, and to use any grant proceeds solely for the advancement of the Licensed Technology pursuant to the terms of this collaboration, subject to the terms and conditions of the grant award. Each party agrees to cooperate
with and reasonably assist the other in the pursuit of such grant funding. 
 6. Confidentiality. In connection with the implementation of this
Agreement, Assignee may receive confidential, scientific, financial, or product information from Assignor, and Assignor may receive the same from Assignee. including information relating to Licensed Technology. Such information. when given in
writing, shall lie marked or otherwise identified as confidential when disclosed or, in the case of information given verbally, shall be identified as confidential at the time of such verbal disclosure. Both parties shall maintain the
confidentiality of the Confidential Information received from the other party, not disclose it to others (except with the permission of the disclosing party), and use it only in connection with this Agreement. Both parties will use reasonable
efforts to assure that all of their employees, consultants, contractors and others who have access to Confidential Information through them comply with the confidentiality obligations of this section. The parties’ obligation shall not apply to
Confidential Information which: (i) was in the receiving party’s possession as evidenced by written records prior to disclosure for the ocher party; (ii) was at the time of disclosure or becomes public through no fault of the
receiving party; (iii) is disclosed to the receiving party by a third party who has no obligation of confidentiality to the disclosing party; (iv) is independently developed by the receiving party without use of such Confidential
Information of the other party. A party receiving Confidential Information may disclose such information as required by law, court order, or order of an administrative agency to be disclosed, provided, however, that notice of such potential legally
required disclosure shall be provided to the disclosing party so the disclosing party may seek a protective order, and the receiving party shall assist the disclosing party in the event the disclosing party seeks to obtain such a protective order or
use other legal means to protect the confidential nature of the information. This section shall survive termination of this Agreement. 

Signed effective as of the date first written above. 

ASSIGNEE: CONVERGEN LIFESCIENCES, INC. 
  

					
		 	 By:
	 	 /s/ DAVID G. NANCE

		 		 	 David G. Nance, Chairman

 ASSIGNOR: GENSOLVE, INC. 
  

					
		 	 By:
	 	 /s/ RODNEY VARNER

		 		 	 Rodney Varner, President

 ANNEX A 

ASSIGNMENT AND COLLABORATION AGREEMENT 
  

	1.	“Sublicense” means the Technology Sublicense Agreement between Introgen Therapeutics, Inc. and Assignor dated March 7, 2007. 

 

	2.	“Assignor” means Introgen Research Institute, Inc., a Delaware corporation, doing business as Gensolve, Inc. 

  

	3.	“Assignee” means Convergen LifeSciences, Inc., a Delaware corporation. 

  

	4.	“NIH” means National Institutes of Health, an agency of the United States Department of Human Services. 

  

	5.	“Licensed Technology” means the Licensed Subject Matter as defined in the Sublicense.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00274-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00274-of-00352.parquet"}]]